• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Pediatrix Medical Group Inc.

    10/31/24 11:54:57 AM ET
    $MD
    Hospital/Nursing Management
    Health Care
    Get the next $MD alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    Pediatrix Medical Group Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    58502B106


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 58502B106

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Dimensional Fund Advisors LP
    30-0447847
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [X]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware Limited Partnership

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 3,126,638** see Note 1 **
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 3,273,961** see Note 1 **
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,273,961 ** see Note 1 **
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Pediatrix Medical Group Inc
    (b) Address of Issuer's Principal Executive Offices
    1301 Concord Terrace, Sunrise, FL 33323
    Item 2.
    (a) Name of Person Filing
    Dimensional Fund Advisors LP
    (b) Address of Principal Business Office or, if None, Residence
    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c) Citizenship
    Delaware Limited Partnership
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    58502B106
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    3,273,961 ** see Note 1 **
    (b) Percent of Class:
    3.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 3,126,638** see Note 1 **
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 3,273,961** see Note 1 **
    (iv) shared power to dispose or to direct the disposition of 0
    ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dimensional Fund Advisors LP
    By: Dimensional Holdings Inc., General Partner
    By: /s/ Selwyn Notelovitz
    Date: October 31, 2024
    Name: Selwyn Notelovitz
    Title: Global Chief Compliance Officer

    Get the next $MD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MD

    DatePrice TargetRatingAnalyst
    12/16/2024Outperform
    Macquarie
    9/26/2024$8.00 → $14.00Hold → Buy
    Jefferies
    6/7/2024$8.00Sell → Hold
    Deutsche Bank
    2/23/2022$32.00 → $31.00Outperform
    Credit Suisse
    12/22/2021$33.00 → $32.00Outperform
    Credit Suisse
    11/4/2021$29.00 → $27.00Market Perform
    SVB Leerink
    9/27/2021$29.00Market Perform
    SVB Leerink
    8/9/2021$30.00 → $32.00Neutral
    Mizuho
    More analyst ratings

    $MD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pediatrix Medical Group Reports First Quarter Results

      Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

      5/6/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

      Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across

      4/21/25 7:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Reports Fourth Quarter Results

      Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

      2/20/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    SEC Filings

    See more
    • Pediatrix Medical Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/8/25 4:30:14 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • SEC Form 10-Q filed by Pediatrix Medical Group Inc.

      10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/6/25 7:00:19 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/6/25 6:50:08 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Financials

    Live finance-specific insights

    See more
    • Pediatrix Medical Group Reports First Quarter Results

      Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

      5/6/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

      Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across

      4/21/25 7:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Reports Fourth Quarter Results

      Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

      2/20/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Macquarie initiated coverage on Pediatrix Medical Group

      Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform

      12/16/24 7:46:05 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group upgraded by Jefferies with a new price target

      Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously

      9/26/24 7:37:57 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00

      6/7/24 8:14:20 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, GC, Chief Admin Off & Sec Moore Mary Ann E gifted 26,497 shares, decreasing direct ownership by 21% to 100,338 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/7/25 5:00:10 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • EVP, CFO and Treasurer Rossi Kasandra H covered exercise/tax liability with 3,718 shares, decreasing direct ownership by 7% to 51,151 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/4/25 5:00:09 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • EVP, GC, Chief Admin Off & Sec Moore Mary Ann E covered exercise/tax liability with 8,975 shares, decreasing direct ownership by 7% to 126,835 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/4/25 5:00:17 PM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pediatrix Medical Group Inc.

      SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      11/13/24 4:30:24 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pediatrix Medical Group Inc.

      SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      10/31/24 11:54:57 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G/A filed by Pediatrix Medical Group Inc. (Amendment)

      SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      6/10/24 12:43:02 PM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Leadership Updates

    Live Leadership Updates

    See more
    • Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation

      Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex

      1/13/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Board Appoints Sylvia Young as Independent Director

      Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu

      5/4/23 4:05:00 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • BurgerFi Appoints Vivian Lopez-Blanco to its Board of Directors

      PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof

      7/15/21 7:30:00 AM ET
      $BFI
      $TAST
      $MD
      Restaurants
      Consumer Discretionary
      Hospital/Nursing Management
      Health Care